[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100492777":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":20,"studyPopulation":20,"armGroups":27,"interventions":34,"overallOfficials":40,"centralContacts":44,"locations":54,"responsibleParty":101,"collaborators":20,"id":103,"slug":104,"hasResults":105,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":20,"eligibilityCriteria":109,"healthyVolunteers":105,"sex":110,"minAge":111,"maxAge":20,"enrollmentInfo":112,"targetDuration":20,"studyType":115,"phases":116,"briefSummary":117,"conditions":118,"keywords":20,"overallStatus":57,"whyStopped":20,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},{"fullName":5,"class":6},"New World Medical, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":20},[9],{"measure":10,"description":11,"timeFrame":12},"IOP change","Reduction in unmedicated IOP","Month12",[14,17],{"measure":15,"description":16,"timeFrame":12},"IOP","Percentage Change in unmedicated IOP",{"measure":18,"description":19,"timeFrame":12},"IOP meds","Change in number of IOP lowering medications",null,{"allocation":22,"interventionModel":23,"interventionModelDescription":20,"primaryPurpose":24,"observationalModel":20,"timePerspective":20,"maskingInfo":25},"NA","SINGLE_GROUP","TREATMENT",{"masking":26,"maskingDescription":20,"whoMasked":20},"NONE",[28],{"label":29,"type":30,"description":31,"interventionNames":32},"Treatment with a Canaloplasty Device","OTHER","US. FDA Approved Canaloplasty Device",[33],"Device: Canaloplasty Device",[35],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":20},"DEVICE","Canaloplasty Device","Canaloplasty",[29],[41],{"name":42,"affiliation":5,"role":43},"Mini Balaram, MD","STUDY_DIRECTOR",[45,50],{"name":46,"role":47,"phone":48,"phoneExt":20,"email":49},"Swetha Mandava, MS","CONTACT","9732049467","smandava@newworldmedical.com",{"name":51,"role":47,"phone":52,"phoneExt":20,"email":53},"Elysia Ison, OD,FAAO","4083487408","eison@newworldmedical.com",[55,70,87],{"facility":56,"status":57,"city":58,"state":20,"zip":20,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"Centro de la Vision","RECRUITING","Santiago","Chile","CL",{"type":62,"coordinates":63},"Point",[64,65],-70.64827,-33.45694,{"lat":65,"lon":64},[68],{"name":69,"role":47,"phone":20,"phoneExt":20,"email":20},"Edison Villagran",{"facility":71,"status":57,"city":72,"state":20,"zip":20,"country":73,"countryCode":74,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Clínica 20\u002F20","San José","Costa Rica","CR",{"type":62,"coordinates":76},[77,78],-84.08489,9.93388,{"lat":78,"lon":77},[81,84],{"name":82,"role":47,"phone":83,"phoneExt":20,"email":20},"Nadja Dodero","+506 8375-8263",{"name":85,"role":86,"phone":20,"phoneExt":20,"email":20},"Claudio Orlich, MD","PRINCIPAL_INVESTIGATOR",{"facility":88,"status":89,"city":90,"state":20,"zip":20,"country":91,"countryCode":92,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Centro Oftalmologico Robles","NOT_YET_RECRUITING","Santa Rosa de Copán","Honduras","HN",{"type":62,"coordinates":94},[95,96],-88.7756,14.77388,{"lat":96,"lon":95},[99],{"name":100,"role":47,"phone":20,"phoneExt":20,"email":20},"Gricelda Ortiz",{"type":102,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100492777","clinical-trial-to-evaluate-the-safety-and-effectiveness-of-a-canaloplasty-device-in-subjects-with-open-angle-glaucoma-100492777",false,"NCT05696561","Clinical Trial to Evaluate the Safety and Effectiveness of a Canaloplasty Device in Subjects With Open-Angle Glaucoma","A Prospective, Multicenter, First in Human Clinical Trial to Evaluate the Safety and Effectiveness of the DF12 CANALOPLASTY AND TRABECULOTOMY SURGICAL SYSTEM in Subjects With Open-Angle Glaucoma Undergoing Cataract Surgery","Inclusion Criteria:\n\n1. Subjects qualifying for cataract surgery\n2. Subjects with diagnosis of open-angle glaucoma in at least one eye with unmedicated IOP of 22-34 mmHg.\n\nExclusion Criteria:\n\n1\\. Patients who cannot be washed-out of IOP-lowering medications.","ALL","22 Years",{"count":113,"type":114},70,"ESTIMATED","INTERVENTIONAL",[22],"Clinical Trial to Evaluate the Safety and Effectiveness of a Canaloplasty Device in Subjects with Open-Angle Glaucoma",[119],"OAG - Open-Angle Glaucoma","2026-02-24",{"date":122,"type":123},"2026-02-27","ACTUAL",{"date":125,"type":123},"2025-09-09",{"date":127,"type":114},"2027-10",{"name":5,"class":6},3]